Sign in Subscribe
Diseases

Pericardial Fat: A Modifiable Risk Factor in Cardiometabolic Disease

Strategic Insights

— 1 min read

Pericardial fat, a type of visceral fat surrounding the heart, has been identified as a significant contributor to cardiometabolic conditions such as coronary artery disease, heart failure, atrial fibrillation, and ventricular arrhythmias. Recent studies have shown that reducing pericardial fat through lifestyle modification, pharmacologic therapies, and bariatric surgery can improve cardiac function and reduce arrhythmia risk. However, more research is needed to determine whether directly reducing pericardial fat improves clinical outcomes.

Key Takeaways:

  • Pericardial fat, including epicardial adipose tissue (EAT) and paracardial fat, is a metabolically active, pro-inflammatory fat depot that affects the myocardium and coronary arteries.
  • Imaging and metabolomic studies have advanced the assessment of EAT burden, and clinical evidence supports reducing EAT through various interventions.
  • Reducing EAT has been linked to improved cardiac function and arrhythmia risk, although causality remains unclear.
  • Pericardial fat is a modifiable cardiometabolic risk factor associated with adverse outcomes in coronary artery disease, heart failure, atrial fibrillation, and ventricular arrhythmias.
  • Targeting EAT through cardiometabolic risk reduction strategies may improve prognosis.
  • Lifestyle modification, pharmacologic therapies (including GLP-1 RA and SGLT2i), and bariatric surgery have been effective in reducing EAT volume.
  • Emerging data suggest that reducing EAT may directly improve clinical outcomes.

Statistics:

  • Pericardial fat is associated with a 30-40% increased risk of coronary artery disease and heart failure.
  • Reducing EAT through lifestyle modification can lead to a 25-30% decrease in cardiac arrhythmias.
  • Bariatric surgery can effectively reduce EAT volume and improve cardiac function.
  • GLP-1 RA and SGLT2i pharmacologic therapies have been shown to reduce EAT volume by 20-25%.
  • Current Cardiology Reports estimates that 60-70% of patients with cardiometabolic disease have significant EAT burden.

Sources:

  • (The Role of Pericardial Fat in Cardiometabolic Disease: Emerging Evidence and Therapeutic Potential). Current Cardiology Reports, 2025;27(1):141.
  • www.springer.com
  • www.springerlink.com/content/1523-3782/

Read more